IonSource Daily Links to 
Mass Spectrometry, Biotechnology and Pharmaceutical  Industry News


IonSource Home | Disclaimer

Note: News stories may be minutes or several days old and should not be used for investment purposes.



04/29/16 Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors
  European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV
04/28/16 Christina Applegate and Merck Urge Insomnia Sufferers to Learn “Why They’re So Awake”
04/27/16 Takeda Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Medicine
04/25/16 Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
04/18/16 Agilent Technologies Introduces First Commercial Software for Metabolic Flux Analysis
04/15/16 Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
04/14/16 U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Supplemental Biologics License Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients
04/11/16 Genentech Announces FDA Grants Venclexta (Venetoclax) Accelerated Approval for People with a Hard-To-Treat Type of Chronic Lymphocytic Leukemia
04/10/16 FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
04/06/16 European Commission Approves Bristol-Myers Squibb’s Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma
04/04/16 U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy
  Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases
04/01/16 Bristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc.
  Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for Treatment of Advanced Melanoma
03/24/16 Appeals Court Upholds Depomed Patents Asserted against Purdue Pharma
03/14/16 FDA Grants Genentech’s Cancer Immunotherapy Atezolizumab Priority Review for Advanced Bladder Cancer
03/07/16 Merck: FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
  Thermo Fisher Scientific Continues to Expand Leading Analytical Instruments Offering for Customers in Applied Markets
  Agilent Technologies Makes $80 Million Investment in Emerging Biotechnology Company Lasergen
03/05/16 GSK presents new data on the long-term efficacy & safety of Nucala® for the treatment of severe asthma with an eosinophilic phenotype
03/04/16 Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa
03/01/16 Amgen Submits Supplemental Biologics License Application For BLINCYTO® For Difficult-to-Treat Type of Pediatric Acute Lymphoblastic Leukemia
  U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
02/29/16 Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma
  FDA approves Roche’s Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma
02/28/16 Genentech Provides Update on Two Identical Phase III Studies of Lebrikizumab in People with Severe Asthma
02/26/16 Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo® (nivolumab) for Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer and Renal Cell Carcinoma
  FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
  FDA Approves Genentech’s Gazyva (Obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
  Japanese MHLW Grants Orphan Drug Designation in Japan to Takeda's Oral Proteasome Inhibitor Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
02/21/16 Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
02/19/16 Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
02/16/16 FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
02/08/16 SCIEX Presents Revolutionary High Resolution Mass Spec System for Routine Testing at ArabLab 2016
01/27/16 Agilent Technologies Wins Award for Innovation in Liquid Chromatography  Dual-Needle Technology Enhances Speed, Flexibility
01/19/16 Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis
  Agilent Technologies Extends Agreement with PerkinElmer on Bioanalyzer Chips
01/15/16 Merck Resolves Previously Disclosed Securities Class Action Lawsuit Related to Vioxx
  Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
01/14/16 Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes
01/13/16 Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
  Pfizer Acquires Treerly and Its Family of Products from Sirio Pharma
01/12/16 Genentech: FDA Grants Priority Review for Venetoclax New Drug Application
  Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
  SCIEX Announces Exclusive Co-Marketing Agreement with Pressure BioSciences, Inc. to Improve Protein Quantitation in Complex Samples
01/11/16 Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration
01/08/16 Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries
  Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
  Thermo Fisher Scientific to Acquire Affymetrix
01/07/16 PROGNOSIS Study Published in The New England Journal of Medicine Reveals Innovative Roche Blood Test Can Be Used as a Predictive Tool for Preeclampsia
01/06/16 GSK: ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection
  Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis
01/05/16 Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
01/04/16 Depomed Announces Closing of Acquisition of U.S. Rights to Cebranopadol From Grunenthal
  Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection
12/21/15 Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases
12/18/15 Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare
12/11/15 FDA Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer
11/08/15 Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients
  New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis
11/07/15 Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis
  GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus
11/05/15 Pfizer Global Analysis Of Metastatic Breast Cancer Landscape Reveals Gaps In Patient Care And Support
  European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Previously Treated Advanced Renal Cell Carcinoma
  Further refugee aid measure:
Bayer donates medicines for refugees in Turkey, Greece and Austria
  Agilent Technologies Signs Instrument Control Exchange Agreement with Thermo Fisher Scientific
  U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
11/04/15 Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer
  GSK’s Nucala® (mepolizumab) receives approval from US FDA  First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype
  Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
11/03/15 Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers
  ISS and Glass Lewis Recommend Horizon Pharma Shareholders Vote AGAINST the Issuance of Horizon Shares in Connection with Horizon's Attempted Takeover of Depomed
11/02/15 New Data Continue to Characterize the Safety and Efficacy of XELJANZ® (tofacitinib citrate) in the Treatment of Rheumatoid Arthritis
  Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc
  Agilent Technologies Completes Acquisition of Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism
  Bruker eDispatch, Issue 63, November 2015 Get the latest news for Separations & Mass Spec with Bruker's eDispatch monthly Newsletter
10/28/15 Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma
  Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product
10/27/15 Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)
10/23/15 Complete Phase 2a Study of HIV-1 Investigational Maturation Inhibitor Demonstrates Positive Results for Therapy Designed to Attack Virus Differently Than Existing Treatments
10/14/15 Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study
10/09/15 Dako, an Agilent Technologies Company, Announces FDA Approval of New Test for Lung Cancer Patients
10/08/15 Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis
10/07/15 Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies
10/06/15 Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020
10/02/15 Bayer CropScience hosts Weed Resistance Global Symposium in Paris:
Knowledge exchange, collaboration and innovation are key to fighting global weed resistance more
  FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
10/01/15 Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
  Bayer CropScience hosts Horticulture Symposium in Mexico:
Joining hands for sustainability and innovation in horticulture
9/30/15 Thermo Fisher Scientific Completes Acquisition of Alfa Aesar to Significantly Expand Laboratory Chemicals Offering
9/29/15 Shimadzu's Nexera MX Ultra Fast Multianalyte LCMS System Offers Excellent Operational Efficiency and Up to Double the Previous Sample Processing Capability
9/28/15 Roche's ocrelizumab first investigational medicine to show efficacy in people with primary progressive multiple sclerosis in large Phase III study
  Bruker Introduces the rapifleX™ MALDI-TOF/TOF at HUPO
9/27/15 Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057
  Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study
9/25/15 Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe
  Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma
  Bruker’s NMR FoodScreener™ Laboratory Achieves ISO/IEC 17025 Accreditation
9/24/15 SCIEX Announces Exclusive Reseller Agreement with Advaita Bioinformatics
  Development of new wheat varieties in Saxony-Anhalt:
Bayer CropScience expands its European Center for Wheat Breeding in Gatersleben
  GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma
9/23/15 New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression
  Agilent Technologies Announces Opening of Life Science Research Center at Carleton University
  Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes
9/16/15 Amgen To Acquire Privately-Held Dezima Pharma
9/9/15 Gilead Prices $10 Billion of Senior Unsecured Notes
9/8/15 FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer
  Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S.

Company News

On-Line Magazines Hot News Sites

BMS Company
Eli Lilly
Incyte Gen.
Life Technologies

LCGC Magazine
Drug Discovery and Development Magazine
New Scientist

Proteomic Company News Links
Check out the Proteomics page at IonSource 

GE News of the Day
ScienceNews On-Line
The Seattle Times
SF Gate Technology News


Archive of old news 

home | disclaimer
Copyright © 2001-2016  IonSource, LLC  All rights reserved. 
Last updated:  Tuesday, May 03, 2016 11:53:29 AM

Hit Counter